Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients

References

• Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep. 2012;9:139–147.
   PubMed Web of Science ®Google Scholar
• Hunt PW. Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep. 2007;4: 42–47.
   PubMedGoogle Scholar
• Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009;338:a3172.
   PubMed Web of Science ®Google Scholar
• Dauby N, De Wit S, Delforge M, Necsoi VC, Clumeck N. Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study. J Int AIDS Soc. 2011;14–16.
   PubMed Web of Science ®Google Scholar
• Benjamin LA, Bryer A, Emsley HC, Khoo S, Solomon T, Connor MD. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012;11:878–890.
   PubMed Web of Science ®Google Scholar
• Gazzola L, Bellistri GM, Tincati C, et al. Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. J Transl Med. 2013;11:51.
   PubMed Web of Science ®Google Scholar
• Kaplan-Lewis E, Aberg JA, Lee M. Aging with HIV in the ART era. Semin Diagn Pathol. 2017;34:384–397.
   PubMed Web of Science ®Google Scholar
• Guihot A, Dentone C, Assoumou L, et al. Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. AIDS 2016;30:327–330.
   PubMed Web of Science ®Google Scholar
• Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep. 2017;14:93–100.
   PubMed Web of Science ®Google Scholar
• Gandhi RT, McMahon DK, Bosch RJ, et al. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathog. 2017;13:e1006285.
   PubMed Web of Science ®Google Scholar
• Zidar DA, Juchnowski S, Ferrari B, et al. Oxidized LDL levels are increased in HIV infection and may drive monocyte activation. J Acquir Immune Defic Syndr. 2015;69:154–160.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Tran TT, Stein JH, et al. Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis. 2015;15:651–660.
   Web of Science ®Google Scholar
• Estrada V, Monge S, Gómez-Garre D, et al. Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy. J Int AIDS Soc. 2014;17:19544.
   PubMed Web of Science ®Google Scholar
• Estébanez M, Stella-Ascariz N, Mingorance J, et al. Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study. BMC Infect Dis 2014;14:379.
   PubMed Web of Science ®Google Scholar
• Hattab S, Guihot A, Guiguet M, et al. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. BMC Infect Dis. 2014;14:122.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012;26:1371–1385.
   PubMed Web of Science ®Google Scholar
• Miro JM, Manzardo C, Ferrer E, et al. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1-infected patients starting efavirenz, lopinavir-ritonavir, or atazanavir-ritonavir plus tenofovir/emtricitabine: final 48-week results (The Advanz-3 Trial). J Acquir Immune Defic Syndr. 2015;69:206–215.
   PubMed Web of Science ®Google Scholar
• Hileman CO, Kinley B, Scharen-Guivel V, et al. Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor-based initial antiretroviral therapy among HIV-infected individuals. J Infect Dis. 2015;212:345–354.
   PubMed Web of Science ®Google Scholar
• Ketlogetswe KS, Post WS, Li X, et al. Lower adiponectin is associated with subclinical cardiovascular disease among HIV-infected men. AIDS 2014;28:901–909.
   PubMed Web of Science ®Google Scholar
• Suda J, Dara L, Yang L, et al. Knockdown of RIPK1 markedly exacerbates murine immune-mediated liver injury through massive apoptosis of hepatocytes, independent of necroptosis and inhibition of NF-κB. J Immunol. 2016;197:3120–3129.
   PubMed Web of Science ®Google Scholar
• Parodi A, Kalli F, Svahn J, et al. Impaired immune response to Candida albicans in cells from Fanconi anemia patients. Cytokine. 2015;73:203–207
   PubMed Web of Science ®Google Scholar
• Martinez E. Gonzalez-Cordon A, Ferrer E, et al. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial. Clin Infec Dis. 2015;60:811–820.
   Google Scholar
• Saumoy M. Ordóñez-Llanos J, Martínez E, et al. Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. J Antimicrob Chemother. 2015;70:1130–1138.
   PubMed Web of Science ®Google Scholar
• Gonzales-Cordon A, Domenech M, Camafort M, et al. Subclinical CV disease in patients starting contemporary protease inhibitors. HIV Med. 2018.
   Web of Science ®Google Scholar
• Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multi cohort study. Lancet HIV 2018;5:e291–e300.
   PubMed Web of Science ®Google Scholar
• Lagathu C, Cossarizza A, Bereziat V, Nasi M, Capeau J, Pinti M. Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers. AIDS 2017;31:S105–S119.
   PubMed Web of Science ®Google Scholar